These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 234295

  • 1. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
    Lieberman R, Wybran J, Epstein W.
    Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
    [Abstract] [Full Text] [Related]

  • 2. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
    Cohen MH, Jessup JM, Felix EL, Weese JL, Herberman RB.
    Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
    [Abstract] [Full Text] [Related]

  • 3. Immunopathologic changes in patients with cutaneous malignant melanoma following intratumoral inoculation BCG: correlation with cell-mediated immunity.
    Lieberman R, Epstein W, Fudenberg HH.
    Int J Cancer; 1974 Sep 15; 14(3):401-16. PubMed ID: 4617711
    [No Abstract] [Full Text] [Related]

  • 4. The use of oral BCG in the treatment or metastatic malignant melanoma.
    Pritchard KI, Cowan DH, Baker MA, Osoba D, Phillips RA, Clark DA.
    Med Pediatr Oncol; 1976 Sep 15; 2(2):173-81. PubMed ID: 785199
    [Abstract] [Full Text] [Related]

  • 5. Immunology and cutaneous malignant melanoma.
    Sober AJ.
    Int J Dermatol; 1976 Sep 15; 15(1):1-18. PubMed ID: 1107238
    [No Abstract] [Full Text] [Related]

  • 6. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
    Berd D, Mastrangelo MJ.
    Cancer Invest; 1988 Sep 15; 6(3):337-49. PubMed ID: 3167614
    [Abstract] [Full Text] [Related]

  • 7. Prolonged BCG treatment of melanoma: does it suppress the immune capacity?
    Helander I, Nordman E, Häkkinen IP, Toivanen A.
    Br J Dermatol; 1979 Oct 15; 101(4):421-7. PubMed ID: 508607
    [Abstract] [Full Text] [Related]

  • 8. [Studies on the immune status of melanoma patients: cell-mediated immune reactions in intracutaneous and epicutaneous tests in the lymphocyte transformation test and the leukocyte-migration inhibition test before and during BCG immunotherapy (author's transl)].
    Knopf B, Wätzig V, Knöll B.
    Arch Geschwulstforsch; 1978 Oct 15; 48(8):722-8. PubMed ID: 753194
    [Abstract] [Full Text] [Related]

  • 9. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
    Kokoschka EM, Cerni C, Micksche M.
    Oncology; 1977 Oct 15; 34(5):229-33. PubMed ID: 917456
    [Abstract] [Full Text] [Related]

  • 10. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.
    Seigler HF, Shingleton WW, Pickrell KL.
    Plast Reconstr Surg; 1975 Mar 15; 55(3):294-8. PubMed ID: 1118487
    [Abstract] [Full Text] [Related]

  • 11. Results of administering B.C.G. to patients with melanoma.
    Grant RM, Mackie R, Cochran AJ, Murray EL, Hoyle D, Ross C.
    Lancet; 1974 Nov 09; 2(7889):1096-100. PubMed ID: 4139404
    [No Abstract] [Full Text] [Related]

  • 12. In vitro assay of cell-mediated immunity in BCG therapy of malignant melanoma: a preliminary report.
    Nathanson L, Clark DA.
    Natl Cancer Inst Monogr; 1973 Dec 09; 39():221-4. PubMed ID: 4595321
    [No Abstract] [Full Text] [Related]

  • 13. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
    Henz BM, Macher E, Bröcker EB, Suciu S, Steerenberg PA, Jung E, Rümke P.
    Dermatology; 1996 Dec 09; 193(2):105-9. PubMed ID: 8884144
    [Abstract] [Full Text] [Related]

  • 14. Intralesional immune therapy: methanol extraction residue of BCG or purified protein derivative.
    Lokich JJ, Garnick MB, Legg M.
    Oncology; 1979 Dec 09; 36(5):236-41. PubMed ID: 481845
    [Abstract] [Full Text] [Related]

  • 15. Intralesional immunotherapy of melanoma with BCG.
    Rosenberg SA, Rapp HJ.
    Med Clin North Am; 1976 May 09; 60(3):419-30. PubMed ID: 1271887
    [Abstract] [Full Text] [Related]

  • 16. Immunotherapy for human malignant melanoma.
    Kopf AW.
    South Med J; 1975 Apr 09; 68(4):495-503. PubMed ID: 1124416
    [Abstract] [Full Text] [Related]

  • 17. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
    Trapeznikov NN, Iavorskiĭ VV, Kadagidze ZG, Malaev SG, Kupin VI.
    Vopr Onkol; 1977 Apr 09; 23(8):27-33. PubMed ID: 906404
    [Abstract] [Full Text] [Related]

  • 18. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases.
    Mastrangelo MJ, Bellet RE, Berkelhammer J, Clark WH.
    Cancer; 1975 Oct 09; 36(4):1305-8. PubMed ID: 1175129
    [Abstract] [Full Text] [Related]

  • 19. Intralesional BCG in the treatment of metastatic malignant melanoma.
    Mastrangelo MJ, Sulit HL, Prehn LM, Bornstein RS, Yarbro JW, Prehn RT.
    Cancer; 1976 Feb 09; 37(2):684-92. PubMed ID: 766947
    [Abstract] [Full Text] [Related]

  • 20. Combined immunotherapy in malignant melanoma. Regression of metastatic lesions in two patients concordant in timing with systemic administration of transfer factor and Bacillus Calmette-Guérin.
    Spitler LE, Levin AS, Wybran J.
    Cell Immunol; 1976 Jan 09; 21(1):1-19. PubMed ID: 764975
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.